Sean P Collins1, Cathy A Jenkins2, Frank E Harrell2, Dandan Liu2, Karen F Miller3, Christopher J Lindsell4, Allen J Naftilan5, John A McPherson5, David J Maron6, Douglas B Sawyer7, Neal L Weintraub8, Gregory J Fermann4, Susan K Roll4, Matthew Sperling4, Alan B Storrow3. 1. Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee. Electronic address: sean.collins@vanderbilt.edu. 2. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee. 3. Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio. 5. Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 6. Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California. 7. Department of Medicine, Division of Cardiovascular Medicine, Maine Medical Center, Portland, Maine. 8. Department of Medicine and Vascular Biology Center, Georgia Regents University, Augusta, Georgia.
Abstract
OBJECTIVES: No prospectively derived or validated decision tools identify emergency department (ED) patients with acute heart failure (AHF) at low risk for 30-day adverse events who are thus potential candidates for safe ED discharge. This study sought to accomplish that goal. BACKGROUND: The nearly 1 million annual ED visits for AHF are associated with high proportions of admissions and consume significant resources. METHODS: We prospectively enrolled 1,033 patients diagnosed with AHF in the ED from 4 hospitals between July 20, 2007, and February 4, 2011. We used an ordinal outcome hierarchy, defined as the incidence of the most severe adverse event within 30 days of ED evaluation (acute coronary syndrome, coronary revascularization, emergent dialysis, intubation, mechanical cardiac support, cardiopulmonary resuscitation, and death). RESULTS: Of 1,033 patients enrolled, 126 (12%) experienced at least one 30-day adverse event. The decision tool had a C statistic of 0.68 (95% confidence interval: 0.63 to 0.74). Elevated troponin (p < 0.001) and renal function (p = 0.01) were significant predictors of adverse events in our multivariable model, whereas B-type natriuretic peptide (p = 0.09), tachypnea (p = 0.09), and patients undergoing dialysis (p = 0.07) trended toward significance. At risk thresholds of 1%, 3%, and 5%, we found 0%, 1.4%, and 13.0% patients were at low risk, with negative predictive values of 100%, 96%, and 93%, respectively. CONCLUSIONS: The STRATIFY decision tool identifies ED patients with AHF who are at low risk for 30-day adverse events and may be candidates for safe ED discharge. After external testing, and perhaps when used as part of a shared decision-making strategy, it may significantly affect disposition strategies. (Improving Heart Failure Risk Stratification in the ED [STRATIFY]; NCT00508638).
OBJECTIVES: No prospectively derived or validated decision tools identify emergency department (ED) patients with acute heart failure (AHF) at low risk for 30-day adverse events who are thus potential candidates for safe ED discharge. This study sought to accomplish that goal. BACKGROUND: The nearly 1 million annual ED visits for AHF are associated with high proportions of admissions and consume significant resources. METHODS: We prospectively enrolled 1,033 patients diagnosed with AHF in the ED from 4 hospitals between July 20, 2007, and February 4, 2011. We used an ordinal outcome hierarchy, defined as the incidence of the most severe adverse event within 30 days of ED evaluation (acute coronary syndrome, coronary revascularization, emergent dialysis, intubation, mechanical cardiac support, cardiopulmonary resuscitation, and death). RESULTS: Of 1,033 patients enrolled, 126 (12%) experienced at least one 30-day adverse event. The decision tool had a C statistic of 0.68 (95% confidence interval: 0.63 to 0.74). Elevated troponin (p < 0.001) and renal function (p = 0.01) were significant predictors of adverse events in our multivariable model, whereas B-type natriuretic peptide (p = 0.09), tachypnea (p = 0.09), and patients undergoing dialysis (p = 0.07) trended toward significance. At risk thresholds of 1%, 3%, and 5%, we found 0%, 1.4%, and 13.0% patients were at low risk, with negative predictive values of 100%, 96%, and 93%, respectively. CONCLUSIONS: The STRATIFY decision tool identifies ED patients with AHF who are at low risk for 30-day adverse events and may be candidates for safe ED discharge. After external testing, and perhaps when used as part of a shared decision-making strategy, it may significantly affect disposition strategies. (Improving Heart Failure Risk Stratification in the ED [STRATIFY]; NCT00508638).
Authors: Erik P Hess; Dipti Agarwal; Subhash Chandra; Mohammed H Murad; Patricia J Erwin; Judd E Hollander; Victor M Montori; Ian G Stiell Journal: CMAJ Date: 2010-06-07 Impact factor: 8.262
Authors: Karel G M Moons; Andre Pascal Kengne; Mark Woodward; Patrick Royston; Yvonne Vergouwe; Douglas G Altman; Diederick E Grobbee Journal: Heart Date: 2012-03-07 Impact factor: 5.994
Authors: Adrian F Hernandez; Melissa A Greiner; Gregg C Fonarow; Bradley G Hammill; Paul A Heidenreich; Clyde W Yancy; Eric D Peterson; Lesley H Curtis Journal: JAMA Date: 2010-05-05 Impact factor: 56.272
Authors: JoAnn Lindenfeld; Nancy M Albert; John P Boehmer; Sean P Collins; Justin A Ezekowitz; Michael M Givertz; Stuart D Katz; Marc Klapholz; Debra K Moser; Joseph G Rogers; Randall C Starling; William G Stevenson; W H Wilson Tang; John R Teerlink; Mary N Walsh Journal: J Card Fail Date: 2010-06 Impact factor: 5.712
Authors: Paul A Heidenreich; Justin G Trogdon; Olga A Khavjou; Javed Butler; Kathleen Dracup; Michael D Ezekowitz; Eric Andrew Finkelstein; Yuling Hong; S Claiborne Johnston; Amit Khera; Donald M Lloyd-Jones; Sue A Nelson; Graham Nichol; Diane Orenstein; Peter W F Wilson; Y Joseph Woo Journal: Circulation Date: 2011-01-24 Impact factor: 29.690
Authors: W Frank Peacock; Eugene Braunwald; William Abraham; Nancy Albert; John Burnett; Rob Christenson; Sean Collins; Deborah Diercks; Greg Fonarow; Judd Hollander; Art Kellerman; Mihai Gheorghiade; Doug Kirk; Phil Levy; Alan Maisel; Barry M Massie; Christopher O'Connor; Peter Pang; Monica Shah; George Sopko; Lynne Stevenson; Alan Storrow; John Teerlink Journal: J Am Coll Cardiol Date: 2010-07-27 Impact factor: 24.094
Authors: Douglas S Lee; Thérèse A Stukel; Peter C Austin; David A Alter; Michael J Schull; John J You; Alice Chong; David Henry; Jack V Tu Journal: Circulation Date: 2010-10-18 Impact factor: 29.690
Authors: Sean P Collins; Peter S Pang; Christopher J Lindsell; Demetrios N Kyriacou; Alan B Storrow; Judd E Hollander; J Douglas Kirk; Chadwick D Miller; Richard Nowak; W Frank Peacock; Miguel Tavares; Alexandre Mebazaa; Mihai Gheorghiade Journal: Eur J Heart Fail Date: 2010-08-25 Impact factor: 15.534
Authors: Austin S Kilaru; Nicholas Illenberger; Zachary F Meisel; Peter W Groeneveld; Manqing Liu; Angira Mondal; Nandita Mitra; Raina M Merchant Journal: Circ Cardiovasc Qual Outcomes Date: 2022-09-08
Authors: Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa Journal: Eur J Heart Fail Date: 2017-05-30 Impact factor: 15.534
Authors: Òscar Miró; Xavier Rossello; Elke Platz; Josep Masip; Danielle M Gualandro; W Frank Peacock; Susanna Price; Louise Cullen; Salvatore DiSomma; Mucio Tavares de Oliveira; John Jv McMurray; Francisco J Martín-Sánchez; Alan S Maisel; Christiaan Vrints; Martin R Cowie; Héctor Bueno; Alexandre Mebazaa; Christian Mueller Journal: Eur Heart J Acute Cardiovasc Care Date: 2020-08
Authors: Andrew Doering; Cathy A Jenkins; Alan B Storrow; JoAnn Lindenfeld; Gregory J Fermann; Karen F Miller; Matthew Sperling; Sean P Collins Journal: Int J Emerg Med Date: 2017-05-08